Products

  • 0
  • 0

Inhibiting Enzyme Helps Cancer Immunotherapy Work Better

What is Cancer Immunity
Cancer immunotherapy — a treatment that better enables a patient’s own immune system to attack tumors — has shown great potential against some cancers. Yet immunotherapy doesn’t work against all tumor types, and many patients who initially respond later develop resistance and relapse.
What Motivated this Study?
Researchers from the University of California San Diego School of Medicine and Morse Cancer Center explained: My laboratory is interested in mRNA and its role in many diseases. Let me take a step back: transcribing genes (DNA) into mRNA and then translating them into proteins, the molecules that make up most of our cells. But it is not always that simple. The mRNA can be modified by chemical groups that affect whether it will be translated. These mRNA modifications can be deposited, removed, and interpreted by enzymes called writing, erasing, and reading enzymes. In many species, including humans, the most abundant mRNA modification is called N6-methyladenosine or m6A. We were interested in exploring the role of m6A and its eraser enzyme — called ALKBH5 — in cancer and immunotherapy. To do that, we used CRISPR gene editing to remove the ALKBH5 enzyme in mouse tumor cells, and waited to see what would happen.
Experimental Results and Impact
With the disappearance of ALKBH5, immunotherapy works better in mouse models of refractory melanoma and colon cancer. Compared with ALKBH5 normal mice, the tumors after treatment shrank by about 40% to 70% on average, and the survival time of the mice was prolonged. We have also developed small molecule inhibitors of ALKBH5, which are similar to enzymes in genetic elimination. We also found that people who happen to have genetically deleted the mutation of the ALKBH5 enzyme respond better to anti-PD-1 treatment (a cancer immunotherapy) than people with normal ALKBH5. 80% of ALKBH5 deficient patients have a complete or partial response to anti-PD-1 therapy, while about 50% of ALKBH5 patients with function. This natural experiment gives us hope that if we can develop ALKBH5 inhibitors into new drugs for humans, then we will one day be able to provide an improved combination therapy-immunotherapy plus ALKBH5 inhibitors.
 
 

Inquery us

Our Latest Products

Global colloidal gold market trend 2022-2030 What is Colloidal Gold Used For? by Newsmis-asia

Russian President says if the European Union imposes an oil embargo, Europe will buy energy at the most expensive price and economic activity in Europe will weaken. Rosneft needs to change its business model. Russia will help facilitate settlement an…

Global Graphene oxide market trend 2022-2029 Do you know graphene oxide? by Newsmis-asia

Recently, covid 19 outbreak spreads in Shanghai, China. There are more than 25,000 new asymptomatic domestic infections every day. China is implementing a dynamic zero-out policy. A leading respiratory expert said the key to COVID-19 prevention and c…

Global polycarboxylate superplasticizer ,polycarboxylic acid superplasticizer,pce based superplasticizer market trend 2023-2028 How does polycarboxylate superplasticizer change concrete strength? by Newsmis-asia

A wave of layoffs that has swept the entire Internet industry has intensified. China's Internet industry has experienced several crises and major changes in the past development process. There is also a "brief history of layoffs by major Internet com…